Immune checkpoint inhibitors (ICIs) especially programmed cell death-1 (PD-1) together with its ligand (PD-L1 or B7-H1), have been shown to be essential for the progression of several solid cancers and are likely to become a promising therapeutic target in gastric carcinoma treatment (Coutzac et al., 2019). Here, PDCD1 is linked to gastric carcinoma.